ThesisFrasers Property (Thailand) Public: the risks are mounting — Bangkok condominium oversupply - estimated 50,000+ unsold units in certain price segments creating multi-year absorption…
★ Analysts see FY2027 revenue reaching $12.1B — +0.3% growth in a single year.
What Could Go Wrong
01Bangkok condominium oversupply - estimated 50,000+ unsold units in certain price segments creating multi-year absorption challenge and pricing pressure
02Demographic headwinds - Thailand's aging population and declining household formation rates reduce long-term residential demand growth
03Regulatory changes to foreign ownership restrictions (49% condominium quota) or property taxation could materially impact demand
04Climate risk and flooding exposure in low-lying Bangkok areas affecting property values and insurance costs
05Intense competition from Sansiri, AP Thailand, Pruksa Real Estate, and other major developers with stronger brand recognition in certain segments
06Land scarcity in prime Bangkok locations driving up acquisition costs and compressing development margins
07Shift in buyer preferences toward suburban locations and larger units post-COVID challenging urban high-rise condo model
08Foreign developers (Singapore, Hong Kong-based) entering Thai market with deeper capital resources
value - Stock trades at 0.4x book value suggesting deep value investors betting on asset backing and eventual market recovery.
High sensitivity through multiple channels: (1) Mortgage rates directly impact buyer affordability and demand - Bank of Thailand policy rate…
Watch on earnings: Bank of Thailand policy rate and Thai commercial bank mortgage lending rates, Bangkok condominium presales absorption rate (units sold per month) and average selling price trends, Thai GDP growth rate and private consumption expenditure.
One Sentence Summary:
The bear case: bangkok condominium oversupply - estimated 50,000+ unsold units in certain price segments creating multi-year absorption challenge and pricing.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
